AQR Capital Management’s Spyre Therapeutics SYRE Stock Holding History

AQR Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.04M	Buy	22,937 +2,063	+10%	+$151K	﹤0.01%	2608
2026 Q1	$1.05M	Buy	20,874 +3,054	+17%	+$115K	﹤0.01%	2737
2025 Q4	$584K	Buy	17,820 +773	+5%	+$20.2K	﹤0.01%	2830
2025 Q3	$286K	Sell	17,047 -926	-5%	-$15.1K	﹤0.01%	3106
2025 Q2	$269K	Buy	+17,973	New	+$266K	﹤0.01%	2920
2024 Q4	–	Sell	-35,003	Closed	-$1.03M	–	2949
2024 Q3	$1.03M	Buy	+35,003	New	+$975K	﹤0.01%	1834
2022 Q2	–	Sell	-1,471	Closed	-$85K	–	2294
2022 Q1	$85K	Buy	+1,471	New	+$124K	﹤0.01%	2148
2019 Q4	–	Sell	-428	Closed	-$82K	–	2177
2019 Q3	$82K	Sell	428 -410	-49%	-$79.9K	﹤0.01%	2090
2019 Q2	$143K	Sell	838 -294	-26%	-$50.8K	﹤0.01%	2013
2019 Q1	$228K	Hold	1,132	–	–	﹤0.01%	2042
2018 Q4	$212K	Hold	1,132	–	–	﹤0.01%	2060
2018 Q3	$271K	Buy	1,132 +335	+42%	+$78.2K	﹤0.01%	2132
2018 Q2	$211K	Buy	+797	New	+$196K	﹤0.01%	2211

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

AQR Capital Management's SYRE Position: Q2 2026 in Review

AQR Capital Management increased its Spyre Therapeutics (SYRE) stake by 9.9% in Q2 2026, buying an estimated $151K and bringing the position to 22,937 shares worth $2.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2608.

AQR Capital Management first reported a position in SYRE in Q2 2018 and has held it in 13 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

AQR Capital Management held 22,937 shares of Spyre Therapeutics worth $2.04M as of Q2 2026.
AQR Capital Management bought 2,063 Spyre Therapeutics shares in Q2 2026, an estimated $151K.
Spyre Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2608 holding.
AQR Capital Management first reported a position in Spyre Therapeutics in Q2 2018 and has held it in 13 quarters since.
265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.